Charles River Laboratories | CRL - Current Assets


Charles River Laboratories reported $1.53B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 7.62M Jun/2026
Bio-Rad Laboratories USD 3.02B 78.4M Jun/2026
Bruker USD 2.22B 121.4M Jun/2026
Cardinal Health USD 38.75B 689M Jun/2026
Charles River Laboratories USD 1.53B 40.3M Jun/2026
Cigna USD 46.99B 3.96B Jun/2026
Concord Medical Services Hldg CNY 941.91M 83.42M Dec/2025
CVS Health USD 75.35B 529M Jun/2026
Danaher USD 13.38B 554M Jun/2026
Dentsply International USD 1.93B 83M Jun/2026
Elevance Health USD 67.18B 152M Jun/2026
Humana USD 38.08B 5.35B Mar/2026
Illumina USD 2.83B 96M Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
IQVIA Holdings USD 6.23B 6M Jun/2026
Laboratory Of America USD 3.81B 743.9M Jun/2026
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
McKesson USD 62.84B 5.63B Jun/2026
Merck EUR 13.77B 393M Jun/2026
Mettler Toledo International USD 1.35B 15.48M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Quest Diagnostics USD 2.84B 278M Jun/2026
Revvity USD 2.3B 169.4M Jun/2026
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
UnitedHealth USD 86.86B 4.27B Jun/2026
Veradigm USD 679.65M 131.12M Dec/2022
Waters USD 3.9B 186M Jun/2026
West Pharmaceutical Services USD 1.81B 19.3M Jun/2026